[Increase of antituberculosis efficiency of rifampicin embedded into phospholipid nanoparticles with sodium oleate].

Autor:	Sanzhakov MA; Institute of Biomedical Chemistry, Moscow, Russia., Ipatova OM; Institute of Biomedical Chemistry, Moscow, Russia., Torkhovskaya TI; Institute of Biomedical Chemistry, Moscow, Russia; Scientific Research Institute of Physical-Chemical Medicine, Moscow, Russia., Tikhonova EG; Institute of Biomedical Chemistry, Moscow, Russia; PLC 'IBMH-EcoBioPharm', Moscow, Russia., Medvedeva NV; Institute of Biomedical Chemistry, Moscow, Russia., Zakharova TS; Institute of Biomedical Chemistry, Moscow, Russia., Prozorovskiy VN; Institute of Biomedical Chemistry, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Biomeditsinskaia khimiia [Biomed Khim] 2018 Nov; Vol. 64 (6), pp. 505-510.
DOI:	10.18097/PBMC20186406505
Abstrakt:	The formulation of the antituberculosis drug rifampicin embedded into 20-30 nm nanoparticles from soy phosphatidylcholine and sodium oleate, is characterized by greater bioavailability as compared with free drug substance. In this study higher antituberculosis activity of this formulation was shown. Rifampicin in nanoparticles demonstrated more effective inhibition of M. tuberculosis H37Rv growth: minimal inhibiting concentration (MIC) was twice smaller than for free rifampicin. Administration of this preparation to mice with tuberculosis induced by M. tuberculosis Erdman revealed that after 6 weeks of oral administration the CUF value in lung was 22 times smaller for rifampicin in nanoparticles than for free drug (1.7 un. vs. 37.4 un.). The LD50 value in mice was two fold higher for rifampicin in nanoformulation.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu